Cancer Family
Neoplasm
CI-CAN-00000001Explore in graph →
Non-malignant22,971 active trials259 approved drugs4,031 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000001Explore in graph →
Clinical trials
105,884 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01830322 | Safety and Effectiveness Study of CPI-613 and/or Gemcitabine to Treat Metastatic Pancreatic Cancer | withdrawn | Phase 2 | 0 | Cornerstone PharmaceuticalsINDUSTRY | 1 | Aug 14, 2013 | clinicaltrials |
| NCT01518140 | BiPAP-Vapotherm RCT | withdrawn | Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Aug 13, 2013 | clinicaltrials |
| NCT01105390 |
| AMG 102, Pemetrexed Disodium, and Cisplatin in Treating Patients With Malignant Pleural Mesothelioma |
| withdrawn |
| Phase 2 |
| 0 |
| National Cancer Institute (NCI)NIH |
| 0 |
| Aug 2, 2013 |
| clinicaltrials |
| NCT01690871 | A Phase II Study of Orally Administered BEZ235 Monotherapy in Patients With Metastatic or Unresectable Malignant PEComa | withdrawn | Phase 2 | 0 | Novartis PharmaceuticalsINDUSTRY | 1 | Aug 2, 2013 | clinicaltrials |
| NCT01728181 | A Phase I/II Study of Tivozanib and Erlotinib as Initial Treatment for Metastatic Non-small Cell Lung Cancer Assigned by VeriStrat® Serum Proteomic Evaluation | withdrawn | Phase 1 / Phase 2 | 0 | University of UtahOTHER | 0 | Jul 25, 2013 | clinicaltrials |
| NCT00026468 | Exisulind in Preventing Polyps in Patients With Familial Adenomatous Polyposis | withdrawn | Phase 2 / Phase 3 | 0 | University of UtahOTHER | 0 | Jul 24, 2013 | clinicaltrials |
| NCT00025519 | Peripheral Stem Cell Transplantation in Treating Patients With Metastatic or Recurrent Kidney Cancer | withdrawn | Phase 2 | 0 | Fox Chase Cancer CenterOTHER | 0 | Jul 11, 2013 | clinicaltrials |
| NCT00003455 | Antineoplaston Therapy in Treating Women With Advanced Breast Cancer | withdrawn | Phase 2 | 0 | Burzynski Research InstituteOTHER | 1 | Jul 10, 2013 | clinicaltrials |
| NCT00003486 | Antineoplaston Therapy in Treating Patients With Colon Cancer | withdrawn | Phase 2 | 0 | Burzynski Research InstituteOTHER | 1 | Jul 10, 2013 | clinicaltrials |
| NCT00003502 | Antineoplaston Therapy in Treating Patients With Mantle Cell Lymphoma | withdrawn | Phase 2 | 0 | Burzynski Research InstituteOTHER | 1 | Jul 10, 2013 | clinicaltrials |
| NCT00003505 | Antineoplaston Therapy in Treating Patients With Primary Central Nervous System Lymphoma | withdrawn | Phase 2 | 0 | Burzynski Research InstituteOTHER | 1 | Jul 10, 2013 | clinicaltrials |
| NCT00003514 | Antineoplaston Therapy in Treating Patients With Neuroendocrine Tumor That Is Metastatic or Unlikely to Respond to Surgery or Radiation Therapy | withdrawn | Phase 2 | 0 | Burzynski Research InstituteOTHER | 1 | Jul 10, 2013 | clinicaltrials |
| NCT00003517 | Antineoplaston Therapy in Treating Patients With Stage III or Stage IV Prostate Cancer | withdrawn | Phase 2 | 0 | Burzynski Research InstituteOTHER | 1 | Jul 10, 2013 | clinicaltrials |
| NCT00003536 | Methotrexate With or Without Antineoplaston Therapy in Treating Postmenopausal Women With Advanced Refractory Breast Cancer | withdrawn | Phase 2 | 0 | Burzynski Research InstituteOTHER | 1 | Jul 10, 2013 | clinicaltrials |
| NCT00040989 | BAY 56-3722 in Treating Patients With Recurrent, Unresectable, or Metastatic Kidney Cancer | withdrawn | Phase 2 | 0 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Jul 10, 2013 | clinicaltrials |
| NCT00080613 | Neoadjuvant and Adjuvant Exemestane in Treating Postmenopausal Women With Locally Advanced Hormone Receptor-Positive Breast Cancer | withdrawn | Phase 2 | — | Robert H. Lurie Cancer CenterOTHER | 1 | Jul 10, 2013 | clinicaltrials |
| NCT00084565 | Paclitaxel, Topotecan, and Estramustine in Treating Patients With Metastatic Hormone-Refractory Prostate Cancer | withdrawn | Phase 2 | 0 | Fox Chase Cancer CenterOTHER | 0 | Jul 10, 2013 | clinicaltrials |
| NCT00085345 | Melphalan, Arsenic Trioxide, and Ascorbic Acid in Treating Patients With Relapsed or Refractory Multiple Myeloma | withdrawn | Phase 2 | 0 | OncotherapeuticsINDUSTRY | 1 | Jul 10, 2013 | clinicaltrials |
| NCT00112879 | Arsenic Trioxide, Ascorbic Acid, Dexamethasone, and Thalidomide in Treating Patients With Multiple Myeloma | withdrawn | Phase 2 | 0 | The Cleveland ClinicOTHER | 1 | Jul 10, 2013 | clinicaltrials |
| NCT00389766 | High-Dose Iodine I 131 Metaiodobenzylguanidine, Topotecan, and Peripheral Stem Cell Transplant in Treating Young Patients With Relapsed Stage 4 Neuroblastoma or Primary Resistant High-Risk Neuroblastoma | withdrawn | Phase 2 | 0 | Children's Cancer and Leukaemia GroupOTHER | 0 | Jul 10, 2013 | clinicaltrials |
| NCT01614184 | Fluorescein for Sentinel Lymph Node Biopsy (SLNB) in Breast Cancer | withdrawn | Phase 1 / Phase 2 | 0 | University of UtahOTHER | 0 | Jul 10, 2013 | clinicaltrials |
| NCT00006267 | Nitrocamptothecin in Treating Patients With Recurrent or Metastatic Ovarian Epithelial or Primary Peritoneal Cancer | withdrawn | Phase 2 | 0 | Gynecologic Oncology GroupNETWORK | 0 | Jul 9, 2013 | clinicaltrials |
| NCT01281943 | Study of Pegylated Liposomal Doxorubicin and Temsirolimus in Patients With Advanced Hepatocellular Cancer | withdrawn | Phase 2 | 0 | Washington University School of MedicineOTHER | 0 | Jul 4, 2013 | clinicaltrials |
| NCT01557764 | Lapatinib With Trastuzumab in Treating Patients With HER2-Negative/HER2 Mutant Metastatic Breast Cancer | withdrawn | Phase 2 | 0 | Washington University School of MedicineOTHER | 0 | Jul 4, 2013 | clinicaltrials |
| NCT00017160 | Combination Chemotherapy, Radiation Therapy, and Surgery in Treating Patients With Primary or Recurrent Sarcoma | withdrawn | Phase 2 | 0 | Radiation Therapy Oncology GroupNETWORK | 2 | Jun 27, 2013 | clinicaltrials |
| NCT01600807 | OSI-906 With Gemcitabine and Erlotinib for Metastatic Ductal Adenocarcinoma of the Pancreas | withdrawn | Phase 1 / Phase 2 | 0 | Dana-Farber Cancer InstituteOTHER | 1 | Jun 26, 2013 | clinicaltrials |
| NCT00776802 | GCS-100LE in Combination With Etoposide and Dexamethasone in Relapsed or Refractory Diffuse Large B-Cell Lymphoma(GCS-100LE) | withdrawn | Phase 1 / Phase 2 | 0 | La Jolla Pharmaceutical CompanyINDUSTRY | 1 | Jun 25, 2013 | clinicaltrials |
| NCT01017822 | Conatumumab, Gemcitabine Hydrochloride, Capecitabine, and Radiation Therapy in Treating Patients With Locally Advanced Pancreatic Cancer | withdrawn | Phase 1 / Phase 2 | 0 | Radiation Therapy Oncology GroupNETWORK | 0 | Jun 24, 2013 | clinicaltrials |
| NCT01115036 | A Panobinostat Presurgery(CLBH589C) | withdrawn | Phase 2 | 0 | Duke UniversityOTHER | 1 | Jun 19, 2013 | clinicaltrials |
| NCT01834183 | Tivozanib + Gemcitabine in Metastatic RCC | withdrawn | Phase 2 | 0 | Dana-Farber Cancer InstituteOTHER | 1 | Jun 19, 2013 | clinicaltrials |
| NCT00369954 | Gemcitabine and Carboplatin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer That Responded to Previous Cisplatin or Carboplatin | withdrawn | Phase 2 | 0 | Gynecologic Oncology GroupNETWORK | 0 | Jun 10, 2013 | clinicaltrials |
| NCT01238146 | Obatoclax Mesylate, Rituximab, and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma | withdrawn | Phase 1 / Phase 2 | 0 | National Cancer Institute (NCI)NIH | 1 | Jun 6, 2013 | clinicaltrials |
| NCT01293942 | IXO+A in mCRC With Liver-only Metastases | withdrawn | Phase 2 | 0 | Ottawa Hospital Research InstituteOTHER | 1 | Jun 5, 2013 | clinicaltrials |
| NCT01540435 | Perioperative Treatment of Resectable Liver Metastases(PERIMAX) | withdrawn | Phase 2 | 0 | University of RegensburgOTHER | 0 | May 29, 2013 | clinicaltrials |
| NCT01733836 | Prostate Cancer Active Surveillance Metformin Trial | withdrawn | Phase 2 | 0 | University Health Network, TorontoOTHER | 1 | May 24, 2013 | clinicaltrials |
| NCT00293527 | Interferon Alpha-2b (Intron A) for Metastatic or Unresectable Clear Cell Renal Carcinoma | withdrawn | Phase 2 | 0 | Ohio State University Comprehensive Cancer CenterOTHER | 0 | May 23, 2013 | clinicaltrials |
| NCT01013506 | Phase 2, Endocrine Therapy + OSI-906 With or Without Erlotinib for Hormone-sensitive Metastatic Breast Cancer | withdrawn | Phase 2 | 0 | Vanderbilt-Ingram Cancer CenterOTHER | 0 | May 23, 2013 | clinicaltrials |
| NCT01736878 | Efficacy and Safety Study of Sorafenib to Treat Advanced Medullary Thyroid Carcinoma(SUMMIT) | withdrawn | Phase 2 | 0 | Eanm Research LtdNETWORK | 1 | May 17, 2013 | clinicaltrials |
| NCT00357461 | Ipilimumab With or Without Vaccine Therapy in Treating Patients With Previously Treated Stage IV Melanoma | withdrawn | Phase 2 | 0 | Bristol-Myers SquibbINDUSTRY | 0 | May 15, 2013 | clinicaltrials |
| NCT00801918 | Denileukine Diftitox for Relapsed ALCL | withdrawn | Phase 2 | 0 | Columbia UniversityOTHER | 1 | May 15, 2013 | clinicaltrials |
| NCT01674374 | Botanical Therapy in Treating Mucositis in Patients With Head and Neck Cancer Who Have Undergone Chemoradiation Therapy | withdrawn | Phase 2 | 0 | Roswell Park Cancer InstituteOTHER | 0 | May 15, 2013 | clinicaltrials |
| NCT00916669 | A Randomized Study to Evaluate the Effect of Two Different Doses of Enoxaparin Sodium in Combination With Standard Chemotherapy in Patients With Stage Small Cell Lung Cancer (SCLC) | withdrawn | Phase 2 | 0 | Massachusetts General HospitalOTHER | 1 | May 8, 2013 | clinicaltrials |
| NCT00577980 | Testosterone in Castration-Resistant Prostate Cancer | withdrawn | Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Apr 29, 2013 | clinicaltrials |
| NCT00268255 | Gefitinib and Radiation Therapy in Treating Patients With Inoperable Stage I or Stage II Non-Small Cell Lung Cancer | withdrawn | Phase 1 / Phase 2 | 0 | Barbara Ann Karmanos Cancer InstituteOTHER | 0 | Apr 16, 2013 | clinicaltrials |
| NCT00487851 | Comparing Endoscopic Based Stent Strategy Versus Bypass Surgery in Non-resectable Periampullary Cancer | withdrawn | Phase 2 | 0 | Karolinska InstitutetOTHER | 1 | Apr 12, 2013 | clinicaltrials |
| NCT01616186 | Everolimus/Sorafenib or Sunitinib in Patients With Metastatic Renal Cell Carcinoma (RCC) | withdrawn | Phase 2 | 0 | Andrea HarzstarkOTHER | 0 | Apr 8, 2013 | clinicaltrials |
| NCT00968396 | Ex-Vivo Depletion of Myeloma Cells From Peripheral Blood Progenitor Cell Grafts | withdrawn | Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Apr 5, 2013 | clinicaltrials |
| NCT01340729 | Open-Label Study of TPI 287 for Patients With Metastatic Melanoma | withdrawn | Phase 1 / Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 5, 2013 | clinicaltrials |
| NCT01427205 | Phase II Study of Cetuximab With or Without OSI-906 in Head and Neck Squamous Cell Carcinoma (HNSCC) | withdrawn | Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Apr 5, 2013 | clinicaltrials |
| NCT00601991 | A Multi-Center Phase 2 Study of VEGF Trap as a Single Agent in Acute Myeloid Leukemia | withdrawn | Phase 2 | 0 | Vanderbilt-Ingram Cancer CenterOTHER | 0 | Apr 2, 2013 | clinicaltrials |
Data updated 23 days agoSource updated Aug 14, 2013source: clinicaltrials